+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Parenteral and Oral), By Drug Type (Analgesics, DMARDs, Corticosteroids), By Country and Growth Forecast, 2023 - 2029

  • PDF Icon

    Report

  • 103 Pages
  • May 2023
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5833539
The Europe Musculoskeletal Disorders Drugs Market should witness market growth of 3.6% CAGR during the forecast period (2023-2029).

Various factors, such as an aging population, sedentary behaviors, obesity, and a higher incidence of work-related injuries, contribute to the rise in incidences and prevalence of musculoskeletal disorders. Consequently, the increase in the number of cases of musculoskeletal disorders has raised the need for treatment options and supported the growth of the market. In addition, an increase in patient awareness regarding the significance of early diagnosis and treatment of MSDs drives the demand. Increased product launches by key participants are expected to impact market growth positively.

The need for musculoskeletal disorder drugs is not limited to developed countries; it is also observed in developing countries, which contributes to the expansion of the market share. In addition, a rise in promotional efforts by manufacturers is anticipated to accelerate the acceptance of such drugs in the near future. Also, the aging population is especially vulnerable to musculoskeletal disorders such as rheumatoid arthritis, osteoarthritis, and osteoporosis. The growing population of senior people has led to a growth in the need for medications to treat musculoskeletal disorders, which in turn has propelled the market for such medications forward.

An investigation conducted by the Ministry of Health in 2015 found that 64.5 percent of Italians over 11 have ingested alcohol at least once. Furthermore, there was additional proof of regular alcohol use between the ages of 11 and 24 that didn't involve meals. It is projected that as more people drink alcohol, adversely affecting numerous organ systems and tissues, including skeletal muscle, the prevalence of musculoskeletal problems will rise. Thus, the need for treatment drugs will rise, driving the market's growth in Europe.

The Germany market dominated the Europe Musculoskeletal Disorders Drugs Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $7,381.3 Million by 2029. The UK market is experiencing a CAGR of 2.7% during (2023-2029). Additionally, The France market would exhibit a CAGR of 4.4% during (2023-2029).

Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Drug Type, the market is segmented into Analgesics, DMARDs, Corticosteroids and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.

Scope of the Study

By Distribution Channel

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Route of Administration

  • Parenteral
  • Oral

By Drug Type

  • Analgesics
  • DMARDs
  • Corticosteroids
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Musculoskeletal Disorders Drugs Market, by Distribution Channel
1.4.2 Europe Musculoskeletal Disorders Drugs Market, by Route of Administration
1.4.3 Europe Musculoskeletal Disorders Drugs Market, by Drug Type
1.4.4 Europe Musculoskeletal Disorders Drugs Market, by Country
1.5 Research Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 The Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Geographical Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Europe Musculoskeletal Disorders Drugs Market by Distribution Channel
4.1 Europe Drug Stores & Retail Pharmacies Market by Country
4.2 Europe Hospital Pharmacies Market by Country
4.3 Europe Online Providers Market by Country
Chapter 5. Europe Musculoskeletal Disorders Drugs Market by Route of Administration
5.1 Europe Parenteral Market by Country
5.2 Europe Oral Market by Country
Chapter 6. Europe Musculoskeletal Disorders Drugs Market by Drug Type
6.1 Europe Analgesics Market by Country
6.2 Europe DMARDs Market by Country
6.3 Europe Corticosteroids Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Musculoskeletal Disorders Drugs Market by Country
7.1 Germany Musculoskeletal Disorders Drugs Market
7.1.1 Germany Musculoskeletal Disorders Drugs Market by Distribution Channel
7.1.2 Germany Musculoskeletal Disorders Drugs Market by Route of Administration
7.1.3 Germany Musculoskeletal Disorders Drugs Market by Drug Type
7.2 UK Musculoskeletal Disorders Drugs Market
7.2.1 UK Musculoskeletal Disorders Drugs Market by Distribution Channel
7.2.2 UK Musculoskeletal Disorders Drugs Market by Route of Administration
7.2.3 UK Musculoskeletal Disorders Drugs Market by Drug Type
7.3 France Musculoskeletal Disorders Drugs Market
7.3.1 France Musculoskeletal Disorders Drugs Market by Distribution Channel
7.3.2 France Musculoskeletal Disorders Drugs Market by Route of Administration
7.3.3 France Musculoskeletal Disorders Drugs Market by Drug Type
7.4 Russia Musculoskeletal Disorders Drugs Market
7.4.1 Russia Musculoskeletal Disorders Drugs Market by Distribution Channel
7.4.2 Russia Musculoskeletal Disorders Drugs Market by Route of Administration
7.4.3 Russia Musculoskeletal Disorders Drugs Market by Drug Type
7.5 Spain Musculoskeletal Disorders Drugs Market
7.5.1 Spain Musculoskeletal Disorders Drugs Market by Distribution Channel
7.5.2 Spain Musculoskeletal Disorders Drugs Market by Route of Administration
7.5.3 Spain Musculoskeletal Disorders Drugs Market by Drug Type
7.6 Italy Musculoskeletal Disorders Drugs Market
7.6.1 Italy Musculoskeletal Disorders Drugs Market by Distribution Channel
7.6.2 Italy Musculoskeletal Disorders Drugs Market by Route of Administration
7.6.3 Italy Musculoskeletal Disorders Drugs Market by Drug Type
7.7 Rest of Europe Musculoskeletal Disorders Drugs Market
7.7.1 Rest of Europe Musculoskeletal Disorders Drugs Market by Distribution Channel
7.7.2 Rest of Europe Musculoskeletal Disorders Drugs Market by Route of Administration
7.7.3 Rest of Europe Musculoskeletal Disorders Drugs Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent Strategies and Developments
8.1.5.1 Partnerships, Collaborations, and Agreements
8.1.6 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent Strategies and Developments
8.2.5.1 Partnerships, Collaborations, and Agreements
8.2.5.2 Acquisition and Mergers
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent Strategies and Developments
8.3.5.1 Approvals and Trials
8.3.5.2 Acquisition and Mergers
8.3.5.3 Geographical Expansions
8.4 UCB S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent Strategies and Developments
8.4.5.1 Partnerships, Collaborations, and Agreements
8.4.5.2 Acquisition and Mergers
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent Strategies and Developments
8.5.5.1 Acquisition and Mergers
8.6 Eli Lilly And Company
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.7 F. Hoffmann-La Roche Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 Merck & Co., Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.9 Novartis AG
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Teva Pharmaceutical Industries Ltd.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses

Companies Mentioned

  • AbbVie, Inc.
  • Amgen, Inc.
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...